AKBA
AKBA
NASDAQ · Biotechnology

Akebia Therapeutics Inc

$1.16
-0.02 (-1.69%)
As of May 10, 10:25 PM ET ·
Analyst Consensus
Strong Buy
11
Analysts
Moderate
Coverage
Buy 10 91%
Hold 1 9%
Sell 0 0%
Price Target
Analyst Price Target +3,128.4% upside
Low Target $22.27
Average Target $37.45
High Target $46.32
Current Price $1.16
Current
$1.16
Target
$37.45
$22.27 $37.45 avg $46.32
Scenario Analysis
Bear Case
$22.27
1,819.8%
Low target
Base Case
$37.45
+3,128.4%
Avg target
Bull Case
$46.32
+3,893.1%
High target
Risk/Reward
2.1x
Favorable
Price in Context
52-Week High
$4.08
-71.6% from high
52-Week Low
$1.13
+2.7% from low
Target vs 52W High
$37.45
+818.2% vs high
Next Earnings Report
May 11, 2026
Today
EPS Est: $-0.03
Earnings in today. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 75% $257.58 +27.8%
AMGN
Amgen Inc
Hold 44 48% $190.87 -42.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
Strong Buy 28 96% $143.40 +41.5%